ÖZ
Amaç
Metabolik sendrom (MetS) abdominal obezite, artmış kan basıncı, glukoz intoleransı ve dislipidemi gibi risk faktörlerinden oluşan bir durum olarak tanımlanmaktadır. MetS dünya çapında önemli bir halk sağlığı sorunudur ve Türkiye'de MetS prevalansı giderek artmaktadır. Serum ferritin konsantrasyonunun MetS’li bireylerde daha yüksek ve enflamasyonun, MetS patogenezinde önemli bir rol oynadığı öne sürülmüştür. Bu çalışmanın amacı MetS olan ve olmayan bireylerde serum ferritin ve enflamatuvar sitokin düzeylerini değerlendirmektir.
Yöntemler
Endokrinoloji ünitesine başvuran 150 kişi, Ulusal Kolesterol Eğitim Programı/Yetişkin Tedavi Paneli (NCEP ATP III) MetS kriterleri temel alınarak her grupta 75 kişi olacak şekilde iki gruba ayrılmıştır. Açlık serum ferritin, interlökin (IL)-1α, IL-10 ve interferon (IFN)-γ düzeyleri ticari enzim bağlantılı immünosorbent test (ELISA) yöntemi ile analiz edilmiştir. Ayrıca demografik parametreler, antropometrik ölçümler ve biyokimyasal parametreler değerlendirilmiştir.
Bulgular
MetS’li bireylerde serum ferritin, IL-1α ve IFN-γ düzeyleri kontrol grubuna kıyasla anlamlı düzeyde yüksek bulunmuştur (p < 0,05). IL-10 düzeyleri hastalarda daha yüksek olmasına rağmen, bu artış istatistiksel olarak anlamlı bulunmamıştır. Ayrıca MetS grubunda, kontrol grubuna göre açlık kan şekeri, trigliserit, kan basıncı, bel çevresi değerleri anlamlı şekilde yüksek; yüksek yoğunluklu lipoprotein-kolesterol düzeyleri ise anlamlı şekilde düşük saptanmıştır.
Sonuç
Bulgular, ferritin, IL-1α ve IFN-γ gibi enflamatuvar belirteçlerin MetS tanı ve yönetiminde potansiyel biyobelirteçler olarak hizmet edebileceğini, patogenezinin daha iyi anlaşılmasına ve erken teşhisine katkıda bulunabileceğini göstermektedir. Bu bulguların doğrulanması için bu değişkenlerin dikkate alındığı daha geniş örneklemli çalışmalara ihtiyaç duyulmaktadır.
Anahtar Kelimeler:
Ferritin, enflamasyon, metabolik sendrom, interlökin-1alfa, interlökin-10, interferon-gama
Kaynaklar
1
Neeland IJ, Lim S, Tchernof A, Gastaldelli A, Rangaswami J, Ndumele CE, et al. Metabolic syndrome. Nat Rev Dis Primers. 2024; 10: 77.
2
International Diabetes Federation. The IDF consensus worldwide definition of the Metabolic Syndrome [Internet]. Brussels: IDF; 2023 [cited 2024 Jun 7]. Available from: https://idf.org/media/uploads/2023/05/attachments-30.pdf
3
Onat A, Yüksel M, Köroğlu B, Gümrükçüoğlu HA, Aydın M, Cakmak HA, et al. TEKHARF 2012: Turkish Adult Risk Factor Study survey 2012: overall and coronary mortality and trends in the prevalence of metabolic syndrome. Turk Kardiyol Dern Ars. 2013; 41: 373–8.
4
Mollaoğlu M, Kars Fertelli T, Özkan Tuncay F. The risk levels of metabolic syndrome and related factors among adults admitted at a village clinic. 2010; 18: 72–9.
5
Serbis A, Giapros V, Galli-Tsinopoulou A, Siomou E. Metabolic syndrome in children and adolescents: ıs there a universally accepted definition? Does it matter? Metab Syndr Relat Disord. 2020; 18: 462–70.
6
Hacışevki A, Berberoğlu HT. Activation of inflammatory signaling pathways in metabolic syndrome: changes in adipokines and cytokines. In: Yucel D, ed. Current Biochemical Studies. Ankara, Akademisyen Kitabevi; 2020: 15–36.
7
Coelho M, Oliveira T, Fernandes R. Biochemistry of adipose tissue: an endocrine organ. Arch Med Sci. 2013; 9: 191–200.
8
Wang W, Knovich MA, Coffman LG, Torti FM, Torti SV. Serum ferritin: past, present and future. Biochim Biophys Acta. 2010; 1800: 760–9.
9
Mahroum N, Alghory A, Kiyak Z, Alwani A, Seida R, Alrais M, et al. Ferritin- from iron, through inflammation and autoimmunity, to COVID-19. J Autoimmun. 2022; 126: 102778.
10
Weir CB, Jan A. BMI classification percentile and cut off points. In: StatPearls [Internet]. Treasure island (FL): StatPearls Publishing; 2025 [cited 2025 Nov 05]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK541070/.
11
National Cholesterol Education Program. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report [Internet]. Bethesda (MD): National Heart, Lung, and Blood Institute; 2002 [cited 2018 Jun 20]. Available from: https://www.nhlbi.nih.gov/files/docs/resources/heart/atp-3-cholesterol-full-report.pdf
12
Valizadeh A, Nikoohemmat M, Ebadinejad A, Soltani S, Tape PMK, Sohrabi A, et al. Metabolic syndrome as a risk factor for the development of kidney dysfunction: a meta-analysis of observational cohort studies. J Diabetes Metab Disord. 2023; 23: 215–27.
13
Srivastav SK, Mir IA, Bansal N, Singh PK, Kumari R, Deshmukh A. Serum ferritin in metabolic syndrome-mechanisms and clinical applications. Pathophysiology. 2022; 29: 319–25.
14
Heeney MM, Andrews NC. Iron homeostasis and inherited iron overload disorders: an overview. Hematol Oncol Clin North Am. 2004; 18: 1379–403.
15
Tran TN, Tran HD, Tran-Huu TT, Tran DM, Tran QN. A cross-sectional study of serum ferritin levels in vietnamese adults with metabolic syndrome. Diabetes Metab Syndr Obes. 2022; 15: 1517–23.
16
Shim YS, Kang MJ, Oh YJ, Baek JW, Yang S, Hwang IT. Association of serum ferritin with insulin resistance, abdominal obesity, and metabolic syndrome in Korean adolescent and adults: The Korean National Health and Nutrition Examination Survey, 2008 to 2011. Medicine (Baltimore). 2017; 96: e6179.
17
Kell DB, Pretorius E. No effects without causes: the ıron dysregulation and dormant microbes hypothesis for chronic, inflammatory diseases. Biol Rev Camb Philos Soc. 2018; 93: 1518–57.
18
Moore Heslin A, O'Donnell A, Buffini M, Nugent AP, Walton J, Flynn A, et al. Risk of ıron overload in obesity and ımplications in metabolic health. Nutrients. 2021; 13: 1539.
19
Eguchi N, Vaziri ND, Dafoe DC, Ichii H. The role of oxidative stress in pancreatic β Cell dysfunction in diabetes. Int J Mol Sci. 2021; 22: 1509.
20
Kilani N, Vollenweider P, Waeber G, Marques-Vidal P. Iron metabolism and incidence of metabolic syndrome. Nutr Metab Cardiovasc Dis. 2015; 25: 1025–32.
21
Dutta D, Maisnam I, Mukhopadhyay S, Raychaudhuri SK, Raychaudhuri SP. Systemic inflammation in psoriasis: sequel of metabolic syndrome. In: Mukhopadhyay S, Mondal S, eds. Metabolic syndrome: from mechanisms to interventions. Academic Press; 2024: 621-33. Available from: https://www.elsevier.com/books/metabolic-syndrome-from-mechanisms-to-interventions/mukhopadhyay/978-0-323-85732–1.
22
Debnath M, Agrawal S, Agrawal A, Dubey GP. Metaflammatory responses during obesity: Pathomechanism and treatment. Obes Res Clin Pract. 2016; 10: 103–13.
23
Guarner V, Rubio-Ruiz ME. Low-grade systemic inflammation connects aging, metabolic syndrome and cardiovascular disease. Interdiscip Top Gerontol. 2015; 40: 99–106.
24
Vona R, Gambardella L, Cittadini C, Straface E, Pietraforte D. Biomarkers of Oxidative Stress in Metabolic Syndrome and Associated Diseases. Oxid Med Cell Longev. 2019; 2019: 8267234.
25
Choi KM, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, et al. Serum adiponectin, interleukin-10 levels and inflammatory markers in the metabolic syndrome. Diabetes Res Clin Pract. 2007; 75: 235–40.
26
Nicoară DM, Munteanu AI, Scutca AC, Mang N, Juganaru I, Brad GF, et al. Assessing the relationship between systemic immune-inflammation index and metabolic syndrome in children with obesity. Int J Mol Sci. 2023; 24: 8414.
27
Ter Horst R, van den Munckhof ICL, Schraa K, Aguirre-Gamboa R, Jaeger M, Smeekens SP, et al. Sex-specific regulation of inflammation and metabolic syndrome in obesity. Arterioscler Thromb Vasc Biol. 2020; 40: 1787–800.
28
Li P, Zhao Y, Wu X, Xia M, Fang M, Iwasaki Y, et al. Interferon gamma (IFN-γ) disrupts energy expenditure and metabolic homeostasis by suppressing SIRT1 transcription. Nucleic Acids Res. 2012; 40: 1609–20.
29
Mirhafez SR, Pasdar A, Avan A, Esmaily H, Moezzi A, Mohebati M, et al. Cytokine and growth factor profiling in patients with the metabolic syndrome. Br J Nutr. 2015; 113: 1911–9.
30
Pacifico L, Di Renzo L, Anania C, Osborn JF, Ippoliti F, Schiavo E, et al. Increased T-helper interferon-γ-secreting cells in obese children. Eur J Endocrinol. 2006; 154: 691–7.
31
Reinehr T, Roth CL. Inflammation markers in type 2 diabetes and the metabolic syndrome in the pediatric population. Curr Diab Rep. 2018; 18: 131.
32
Kamari Y, Werman-Venkert R, Shaish A, Werman A, Harari A, Gonen A, et al. Differential role and tissue specificity of interleukin-1alpha gene expression in atherogenesis and lipid metabolism. Atherosclerosis. 2007; 195: 31–8.
33
Almog T, Kandel Kfir M, Levkovich H, Shlomai G, Barshack I, Stienstra R, et al. Interleukin-1α deficiency reduces adiposity, glucose intolerance and hepatic de-novo lipogenesis in diet-induced obese mice. BMJ Open Diabetes Res Care. 2019; 7: e000650.
34
Ballak DB, Stienstra R, Tack CJ, Dinarello CA, van Diepen JA. IL-1 family members in the pathogenesis and treatment of metabolic disease: focus on adipose tissue inflammation and insulin resistance. Cytokine. 2015; 75: 280–90.
35
Uno T, He J, Usui I, Kanatani Y, Bukhari A, Fujisaka S, et al. Long-term interleukin-1alpha treatment inhibits insulin signaling via IL-6 production and SOCS3 expression in 3T3-L1 adipocytes. Horm Metab Res. 2008; 40: 8–12.
36
de Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Lett. 2008; 582: 97–105.
37
Srikanthan K, Feyh A, Visweshwar H, Shapiro JI, Sodhi K. Systematic review of metabolic syndrome biomarkers: a panel for early detection, management, and risk stratification in the West Virginian population. Int J Med Sci. 2016; 13: 25–38.
38
Esposito K, Pontillo A, Giugliano F, Giugliano G, Marfella R, Nicoletti G, et al. Association of low interleukin-10 levels with the metabolic syndrome in obese women. J Clin Endocrinol Metab. 2003; 88: 1055–8.
39
Barry JC, Shakibakho S, Durrer C, Simtchouk S, Jawanda KK, Cheung ST, et al. Hyporesponsiveness to the anti-inflammatory action of interleukin-10 in type 2 diabetes. Sci Rep. 2016; 6: 21244.
40
Kulshrestha H, Gupta V, Mishra S, Mahdi AA, Awasthi S, Kumar S. Interleukin-10 as a novel biomarker of metabolic risk factors. Diabetes Metab Syndr. 2018; 12: 543–7.
41
Freitas RS, de Souza Silva CM, Ferreira Fratelli C, Ramos de Lima L, Morato Stival M, Schwerz Funghetto S, et al. IL-10 and IL-1β serum levels, genetic variants, and metabolic syndrome: ınsights into older adults’ clinical characteristics. Nutrients. 2024; 16: 1241.
42
Gao M, Zhang C, Ma Y, Bu L, Yan L, Liu D. Hydrodynamic delivery of mIL10 gene protects mice from high-fat diet-induced obesity and glucose intolerance. Mol Ther. 2013; 21: 1852–61.
43
Cintra DE, Pauli JR, Araújo EP, Moraes JC, de Souza CT, Milanski M, et al. Interleukin-10 is a protective factor against diet-induced insulin resistance in liver. J Hepatol. 2008; 48: 628–37.
44
Rodrigues KF, Pietrani NT, Bosco AA, Campos FMF, Sandrim VC, Gomes KB. IL-6, TNF-α, and IL-10 levels/polymorphisms and their association with type 2 diabetes mellitus and obesity in Brazilian individuals. Arch Endocrinol Metab. 2017; 61: 438–46.
45
Medeiros NI, Mattos RT, Menezes CA, Fares RCG, Talvani A, Dutra WO, Rios-Santos F, Correa-Oliveira R, Gomes JAS. IL-10 and TGF-β unbalanced levels in neutrophils contribute to increase inflammatory cytokine expression in childhood obesity. Eur J Nutr. 2018; 57: 2421–30.
46
Calcaterra V, De Amici M, Klersy C, Torre C, Brizzi V, Scaglia F, et al. Adiponectin, IL-10 and metabolic syndrome in obese children and adolescents. Acta Biomed. 2009; 80: 117–23.
47
Yeldu MH, Mus’ab A. Serum biochemical and inflammatory cytokines in a rat model of metabolic syndrome. Asian J Med Sci. 2020; 11: 46–52.
48
Westendorp RG, Langermans JA, Huizinga TW, Elouali AH, Verweij CL, Boomsma DI, et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet. 1997; 349: 170–3.
49
Alqahtani SAM, Alsaleem MA, Ghazy RM. Association between serum ferritin level and lipid profile among diabetic patients: A retrospective cohort study. Medicine (Baltimore). 2024; 103: e37631.
50
Badenhorst CE, Forsyth AK, Govus AD. A contemporary understanding of iron metabolism in active premenopausal females. Front Sports Act Living. 2022; 4: 903937.
